| [1] |
Pui CH, Mullighan CG, Evans WE，et al.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? [J]. Blood，2012，120(6)：1165–1174.
|
| [2] |
Hunger SP, Loh ML, Whitlock JA, et al. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2013，60(6)：957–963.
|
| [3] |
方建培，罗学群，屠立明，等. GZ-2002急性淋巴细胞白血病化疗方案治疗非高危儿童急性淋巴细胞白血病多中心协作临床研究[J]．中国儿童血液与肿瘤杂志，2011，16(4)：60–65.
|
| [4] |
Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study[J]. J Clin Oncol，2010，28(4)：648–654.
|
| [5] |
Malempati S, Gaynon PS, Sather H，et al. Children's Oncology Group outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952[J]. J Clin Oncol, 2007，25(36)：5800–5807.
|
| [6] |
Einsiedel HG, von Stackelberg A, Hartmann R，et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87[J]. J Clin Oncol，2005，23(31): 7942–7950.
|
| [7] |
Von Stackelberg A，Volzke E，Kuhl JS, et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group[J]. Eur J Cancer，2011，47(1)：90–97.
|
| [8] |
Schrauder A, Reiter A, Gadner H, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95[J]. J Clin Oncol, 2006，24(36)：5742–5749.
|
| [9] |
Nemecek ER, Ellis K, He W, et al. Outcome of Myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission[J]. Biol Blood Marrow Transplant, 2011，17(12)：1833–1840.
|
| [10] |
Reismüller B, Peters C, Dworzak MN, et al. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) study group[J]. J Pediatr Hematol Oncol，2013，35(5)：e200–e204.
|
| [11] |
Marshall GM，Dalla Pozza L，Sutton R, et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation[J]. Leukemia, 2013，27(7)：1497–1503.
|
| [12] |
郭海霞，黄科，周敦华，等. 白血病患儿造血干细胞移植后发生眼Kaposi肉瘤一例报告附文献复习[J]. 中华血液学杂志，2013，34(5)：445–448.
|
| [13] |
Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study[J]. Lancet, 2005，366(9486)：635–642.
|
| [14] |
Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia[J]. Lancet Oncol，2013，14(1)：e205–e221.
|
| [15] |
Gaynon PS, Harris RE, Altman AJ, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941[J]. J Clin Oncol，2006，24(19): 3150–3156.
|
| [16] |
Mateos MK, O'Brien TA, Oswald C, et al. Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review[J]. Pediatr Blood Cancer, 2013，60(9)：1520–1527.
|
| [17] |
Borgmann A, von Stackelberg A, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis[J]. Blood，2003，101(10)：3835–3839.
|
| [18] |
Eckert C, Henze G, Seeger K，et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group[J]. J Clin Oncol，2013，31(21)：2736–2742.
|
| [19] |
Tallen G, Ratei R, Mann G, et al: Long-term outcome in children with relapsed acute lympho-blastic leukemia after time-point and site-of-relapse stratification and intensified short course multidrug chemotherapy: results of trial ALL-REZ BFM 90[J]．J Clin Oncol，2010，28(14)：2339–2347.
|
| [20] |
陈静. 儿童恶性血液病异基因造血干细胞移植指征[J/CD]. 中华妇幼临床医学杂志：电子版，2014，10(3)：13–17.
|
| [21] |
Bashir Q，Munsell MF，Giralt S，et al. Randomized phase Ⅱ trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant[J]. Leuk Lymphoma，2012，53(5)：915–919.
|
| [22] |
Lee JH, Yoon HS，Song JS, et al. Unrelated hematopoietic stem cell transplantation for children with acute leukemia: experience at a single institution[J]．J Korean Med Sci，2009, 24(5): 904–909.
|
| [23] |
Lee EJ, Han JY, Lee JW, et al. Outcome of allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission: a single institution study[J]. Korean J Pediatr, 2012，55(3)：100–106.
|
| [24] |
Marshall GM，Dalla Pozza L，Sutton R, et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation[J]．Leukemia，2013，27(7)：1497–1503.
|